# Elosulfase Alfa (Vimizim)

Source: https://ourhealthnetwork.com/drugs/elosulfase-alfa
Data: FDA Orange Book and OpenFDA, refreshed periodically

## What is Elosulfase Alfa?

Elosulfase Alfa (brand name: Vimizim) is a hydrolytic lysosomal glycosaminoglycan-specific enzyme.

## Brand names

Vimizim

## Indications

VIMIZIM (elosulfase alfa) is indicated for patients with Mucopolysaccharidosis type IVA (MPS IVA; Morquio A syndrome). VIMIZIM is a hydrolytic lysosomal glycosaminoglycan (GAG)-specific enzyme indicated for patients with Mucopolysaccharidosis type IVA (MPS IVA; Morquio A syndrome).

## Conditions treated

- [Mucopolysaccharidosis IV](https://ourhealthnetwork.com/conditions/mucopolysaccharidosis-iv)
- [Morquio Syndrome](https://ourhealthnetwork.com/conditions/morquio-syndrome)

## Mechanism of action

Mucopolysaccharidoses comprise a group of lysosomal storage disorders caused by the deficiency of specific lysosomal enzymes required for the catabolism of glycosaminoglycans (GAG). Mucopolysaccharidosis IVA (MPS IVA, Morquio A Syndrome) is characterized by the absence or marked reduction in N -acetylgalactosamine-6-sulfatase activity.

## Drug classification

- Established Pharmacologic Class: Hydrolytic Lysosomal Glycosaminoglycan-specific Enzyme [EPC]
- Route of administration: INTRAVENOUS

## Common side effects

abdominal pain, approximately half of the patients, chills, fatigue, headache, nausea, pyrexia, the majority of patients

## Sources and disclaimers

- FDA Orange Book and OpenFDA dataset
- This information is for educational purposes only and does not constitute medical advice. Always consult a healthcare professional before starting, stopping, or changing any medication.

## Related

- [All drugs](https://ourhealthnetwork.com/drugs)
- [Find specialists who prescribe this drug](https://ourhealthnetwork.com/find-doctors)
- [Methodology](https://ourhealthnetwork.com/methodology)